Cite
Ponomarenko DM, Klimova ID, Chapygina YA, et al. Safety and efficacy of p62 DNA vaccine ELENAGEN in a first-in-human trial in patients with advanced solid tumors. Oncotarget. 2017;8(32):53730-53739doi: 10.18632/oncotarget.16574.
Ponomarenko, D. M., Klimova, I. D., Chapygina, Y. A., Dvornichenko, V. V., Zhukova, N. V., Orlova, R. V., Manikhas, G. M., Zyryanov, A. V., Burkhanova, L. A., Badrtdinova, I. I., Oshchepkov, B. N., Filippova, E. V., Orlov, S. V., Kolesnikov, S. I., Sufianov, A. A., Baum, S. R., Zaitzeva, O. Y., Komissarov, A. B., Grudinin, M. P., Kiselev, O. I., Tsyb, A. F., Venanzi, F., Shcherbinina, V., Chursov, A., Gabai, V. L., & Shneider, A. M. (2017). Safety and efficacy of p62 DNA vaccine ELENAGEN in a first-in-human trial in patients with advanced solid tumors. Oncotarget, 8(32), 53730-53739. https://doi.org/10.18632/oncotarget.16574
Ponomarenko, Dmitry M, et al. "Safety and efficacy of p62 DNA vaccine ELENAGEN in a first-in-human trial in patients with advanced solid tumors." Oncotarget vol. 8,32 (2017): 53730-53739. doi: https://doi.org/10.18632/oncotarget.16574
Ponomarenko DM, Klimova ID, Chapygina YA, Dvornichenko VV, Zhukova NV, Orlova RV, Manikhas GM, Zyryanov AV, Burkhanova LA, Badrtdinova II, Oshchepkov BN, Filippova EV, Orlov SV, Kolesnikov SI, Sufianov AA, Baum SR, Zaitzeva OY, Komissarov AB, Grudinin MP, Kiselev OI, Tsyb AF, Venanzi F, Shcherbinina V, Chursov A, Gabai VL, Shneider AM. Safety and efficacy of p62 DNA vaccine ELENAGEN in a first-in-human trial in patients with advanced solid tumors. Oncotarget. 2017 Mar 25;8(32):53730-53739. doi: 10.18632/oncotarget.16574. eCollection 2017 Aug 08. PMID: 28881846; PMCID: PMC5581145.
Copy
Download .nbib